Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria (original) (raw)

• Matis, L.A. & Rollins, S.A. Complement-specific antibodies: designing novel anti-inflammatories. Nat. Med. 1, 839–842 (1995).
  Article PubMed PubMed Central Google Scholar
• Walport, M.J. Complement. Second of two parts. N. Engl. J. Med. 344, 1140–1144 (2001).
  Article CAS PubMed Google Scholar
• Male, D., Brostoff, J., Roth, D. & Roitt, I. Immunology (Mosby-Elsevier, Philadelphia, 2006).
  Google Scholar
• Abdul Ajees, A. et al. The structure of complement C3b provides insights into complement activation and regulation. Nature 444, 221–225 (2006).
  Article CAS PubMed Google Scholar
• Janssen, B.J. et al. Structures of complement component C3 provide insights into the function and evolution of immunity. Nature 437, 505–511 (2005).
  Article CAS PubMed Google Scholar
• Janssen, B.J., Christodoulidou, A., McCarthy, A., Lambris, J.D. & Gros, P. Structure of C3b reveals conformational changes that underlie complement activity. Nature 444, 213–216 (2006).
  Article CAS PubMed Google Scholar
• Wiesmann, C. et al. Structure of C3b in complex with CRIg gives insights into regulation of complement activation. Nature 444, 217–220 (2006).
  Article CAS PubMed Google Scholar
• Overturf, G.D. Indications for the immunological evaluation of patients with meningitis. Clin. Infect. Dis. 36, 189–194 (2003).
  Article PubMed Google Scholar
• Huber-Lang, M. et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat. Med. 12, 682–687 (2006).
  Article CAS PubMed Google Scholar
• Muller-Eberhard, H.J. Molecular organization and function of the complement system. Annu. Rev. Biochem. 57, 321–347 (1988).
  Article CAS PubMed Google Scholar
• Rabiet, M.J., Huet, E. & Boulay, F. The N-formyl peptide receptors and the anaphylatoxin C5a receptors: an overview. Biochimie 89, 1089–1106 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Chen, N.J. et al. C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a. Nature 446, 203–207 (2007).
  Article CAS PubMed Google Scholar
• Yamashina, M. et al. Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 323, 1184–1189 (1990).
  Article CAS PubMed Google Scholar
• Motoyama, N., Okada, N., Yamashina, M. & Okada, H. Paroxysmal nocturnal hemoglobinuria due to hereditary nucleotide deletion in the HRF20 (CD59) gene. Eur. J. Immunol. 22, 2669–2673 (1992).
  Article CAS PubMed Google Scholar
• Platonov, A.E., Vershinina, I.V., Kuijper, E.J., Borrow, R. & Kayhty, H. Long term effects of vaccination of patients deficient in a late complement component with a tetravalent meningococcal polysaccharide vaccine. Vaccine 21, 4437–4447 (2003).
  Article CAS PubMed Google Scholar
• Thomas, T.C. et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol. Immunol. 33, 1389–1401 (1996).
  Article CAS PubMed Google Scholar
• Riechmann, L., Clark, M., Waldmann, H. & Winter, G. Reshaping human antibodies for therapy. Nature 332, 323–327 (1988).
  Article CAS PubMed Google Scholar
• Weng, N.P., Yu-Lee, L.Y., Sanz, I., Patten, B.M. & Marcus, D.M. Structure and specificities of anti-ganglioside autoantibodies associated with motor neuropathies. J. Immunol. 149, 2518–2529 (1992).
  CAS PubMed Google Scholar
• Klein, R., Jaenichen, R. & Zachau, H.G. Expressed human immunoglobulin kappa genes and their hypermutation. Eur. J. Immunol. 23, 3248–3262 (1993).
  Article CAS PubMed Google Scholar
• Mueller, J.P. et al. Humanized porcine VCAM-specific monoclonal antibodies with chimeric IgG2/G4 constant regions block human leukocyte binding to porcine endothelial cells. Mol. Immunol. 34, 441–452 (1997).
  Article CAS PubMed Google Scholar
• Canfield, S.M. & Morrison, S.L. The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region. J. Exp. Med. 173, 1483–1491 (1991).
  Article CAS PubMed Google Scholar
• Burton, D.R. & Woof, J.M. Human antibody effector function. Adv. Immunol. 51, 1–84 (1992).
  Article CAS PubMed Google Scholar
• Tao, M.H., Smith, R.I. & Morrison, S.L. Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation. J. Exp. Med. 178, 661–667 (1993).
  Article CAS PubMed Google Scholar
• Smith, R.I., Coloma, M.J. & Morrison, S.L. Addition of a mu-tailpiece to IgG results in polymeric antibodies with enhanced effector functions including complement-mediated cytolysis by IgG4. J. Immunol. 154, 2226–2236 (1995).
  CAS PubMed Google Scholar
• Hill, A. et al. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood 106, 2559–2565 (2005).
  Article CAS PubMed Google Scholar
• Wang, Y., Rollins, S.A., Madri, J.A. & Matis, L.A. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc. Natl. Acad. Sci. USA 92, 8955–8959 (1995).
  Article CAS PubMed PubMed Central Google Scholar
• Wang,Y. et al. Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc. Natl. Acad. Sci. USA 93, 8563–8568 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Jain, R.I., Moreland, L.W., Caldwell, J.R., Rollins, S.A. & Mojcik, C.F. A single dose, placebo controlled, double blind, phase I study of the humanized anti-C5 antibody h5G1.1 in patients with rheumatoid arthritis. Arthritis Rheum. 42, S77 (1999).
  Google Scholar
• Rother, R.P., Mojcik, C.F. & McCroskery, E.W. Inhibition of terminal complement: a novel therapeutic approach for the treatment of systemic lupus erythematosus. Lupus 13, 328–334 (2004).
  Article CAS PubMed Google Scholar
• Verrier, E.D. et al. Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial. J. Am. Med. Assoc. 291, 2319–2327 (2004).
  Article CAS Google Scholar
• Armstrong, P.W. et al. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. J. Am. Med. Assoc. 297, 43–51 (2007).
  Article CAS Google Scholar
• Tesser, J. et al. Safety and efficacy of the humanized anti-C5 antibody h5G1.1 in patients with rheumatoid arthritis. Arthritis Rheum. 44, S274 (2001).
  Google Scholar
• Appel, G. et al. Eculizumab (C5 complement inhibitor) in the treatment of idiopathic membranous nephropathy (IMN): Preliminary baseline and pharmacokinetic (PK) /Pharmacodynamic (PD) Data. J. Am. Soc. Nephrol. 13, 668a (2002).
  Google Scholar
• Hill, A. et al. The incidence and prevalence of paroxysmal nocturnal hemoglobinuria (PNH) and survival of patients in Yorkshire. Blood 108, 985 (2006).
  Article CAS Google Scholar
• Parker, C. et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 106, 3699–3709 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Takeda, J. et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 73, 703–711 (1993).
  Article CAS PubMed Google Scholar
• Bessler, M. et al. Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene. EMBO J. 13, 110–117 (1994).
  Article CAS PubMed PubMed Central Google Scholar
• Oni, S.B., Osunkoya, B.O. & Luzzatto, L. Paroxysmal nocturnal hemoglobinuria: evidence for monoclonal origin of abnormal red cells. Blood 36, 145–152 (1970).
  CAS PubMed Google Scholar
• Hu, R. et al. PIG-A mutations in normal hematopoiesis. Blood 105, 3848–3854 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Araten, D.J., Nafa, K., Pakdeesuwan, K. & Luzzatto, L. Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals. Proc. Natl. Acad. Sci. USA 96, 5209–5214 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Dacie, J. [Paroxysmal nocturnal haemoglobinuria.] Sangre (Barc.) 25, 890–895 (1980).
  CAS Google Scholar
• Rotoli, B. & Luzzatto, L. Paroxysmal nocturnal hemoglobinuria. Semin. Hematol. 26, 201–207 (1989).
  CAS PubMed Google Scholar
• Rawstron, A.C. et al. The PNH phenotype cells that emerge in most patients after CAMPATH-1H therapy are present prior to treatment. Br. J. Haematol. 107, 148–153 (1999).
  Article CAS PubMed Google Scholar
• Hansch, G.M., Schonermark, S. & Roelcke, D. Paroxysmal nocturnal hemoglobinuria type III. Lack of an erythrocyte membrane protein restricting the lysis by C5b-9. J. Clin. Invest. 80, 7–12 (1987).
  Article CAS PubMed PubMed Central Google Scholar
• Okada, N., Harada, R. & Okada, H. Erythrocytes of patients with paroxysmal nocturnal hemoglobinuria acquire resistance to complement attack by purified 20-kD homologous restriction factor. Clin. Exp. Immunol. 80, 109–113 (1990).
  Article CAS PubMed PubMed Central Google Scholar
• Holguin, M.H., Fredrick, L.R., Bernshaw, N.J., Wilcox, L.A. & Parker, C.J. Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria. J. Clin. Invest. 84, 7–17 (1989).
  Article CAS PubMed PubMed Central Google Scholar
• Rollins, S.A. & Sims, P.J. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. J. Immunol. 144, 3478–3483 (1990).
  CAS PubMed Google Scholar
• Rosenfeld, S.I., Jenkins, D.E. Jr, & Leddy, J.P. Enhanced reactive lysis of paroxysmal nocturnal hemoglobinuria erythrocytes. Studies on C9 binding and incorporation into high molecular weight complexes. J. Exp. Med. 164, 981–997 (1986).
  Article CAS PubMed Google Scholar
• Brodsky, R.A. Paroxysmal nocturnal hemoglobinuria. in Hematology: Basic Principles and Practice (eds. Hoffman, R. & Benz E. J. Jr. et al.) 419–427 (Churchill Livingstone, Philadelphia, 2005).
  Google Scholar
• Bottomley, A. et al. Health-related quality of life in survivors of locally advanced breast cancer: an international randomised controlled phase III trial. Lancet Oncol. 6, 287–294 (2005).
  Article PubMed Google Scholar
• Cella, D., Lai, J.S., Chang, C.H., Peterman, A. & Slavin, M. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer 94, 528–538 (2002).
  Article PubMed Google Scholar
• Wisloff, F., Gulbrandsen, N., Hjorth, M., Lenhoff, S. & Fayers, P. Quality of life may be affected more by disease parameters and response to therapy than by haemoglobin changes. Eur. J. Haematol. 75, 293–298 (2005).
  Article PubMed Google Scholar
• Rother, R.P., Bell, L., Hillmen, P. & Gladwin, M.T. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. J. Am. Med. Assoc. Review article correlating intravascular hemolysis and cell-free plasma hemoglobin to the clinical sequelae of PNH and other hemolytic diseases 293, 1653–1662 (2005).
  Article CAS Google Scholar
• Hill, A., Rother, R.P. & Hillmen, P. Improvement in the symptoms of smooth muscle dystonia during eculizumab therapy in paroxysmal nocturnal hemoglobinuria. Haematologica 90, ECR40 (2005).
  PubMed Google Scholar
• Gralnick, H.R. et al. Activated platelets in paroxysmal nocturnal haemoglobinuria. Br. J. Haematol. 91, 697–702 (1995).
  Article CAS PubMed Google Scholar
• Audebert, H.J., Planck, J., Eisenburg, M., Schrezenmeier, H. & Haberl, R.L. Cerebral ischemic infarction in paroxysmal nocturnal hemoglobinuria report of 2 cases and updated review of 7 previously published patients. J. Neurol. 252, 1379–1386 (2005).
  Article PubMed Google Scholar
• Hall, C., Richards, S. & Hillmen, P. Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). Blood 102, 3587–3591 (2003).
  Article CAS PubMed Google Scholar
• Olsen, S.B. et al. Enhancement of platelet deposition by cross-linked hemoglobin in a rat carotid endarterectomy model. Circulation 93, 327–332 (1996).
  Article CAS PubMed Google Scholar
• Radomski, M.W., Palmer, R.M. & Moncada, S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 2, 1057–1058 (1987).
  Article CAS PubMed Google Scholar
• Radomski, M.W., Palmer, R.M. & Moncada, S. The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br. J. Pharmacol. 92, 639–646 (1987).
  Article CAS PubMed PubMed Central Google Scholar
• Shao, J. et al. Protective role of nitric oxide in a model of thrombotic microangiopathy in rats. J. Am. Soc. Nephrol. 12, 2088–2097 (2001).
  CAS PubMed Google Scholar
• Catani, M.V., Bernassola, F., Rossi, A. & Melino, G. Inhibition of clotting factor XIII activity by nitric oxide. Biochem. Biophys. Res. Commun. 249, 275–278 (1998).
  Article CAS PubMed Google Scholar
• Kayanoki, Y. et al. Reduced nitric oxide production by L-arginine deficiency in lysinuric protein intolerance exacerbates intravascular coagulation. Metabolism 48, 1136–1140 (1999).
  Article CAS PubMed Google Scholar
• Hillmen, P., Lewis, S.M., Bessler, M., Luzzatto, L. & Dacie, J.V. Natural history of paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 333, 1253–1258 (1995).
  Article CAS PubMed Google Scholar
• Socie, G. et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology. Lancet 348, 573–577 (1996).
  Article CAS PubMed Google Scholar
• Moyo, V.M., Mukhina, G.L., Garrett, E.S. & Brodsky, R.A. Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays. Br. J. Haematol. 126, 133–138 (2004).
  Article CAS PubMed Google Scholar
• Araten, D.J., Thaler, H.T. & Luzzatto, L. High incidence of thrombosis in African-American and Latin-American patients with paroxysmal nocturnal haemoglobinuria. Thromb. Haemost. 93, 88–91 (2005).
  Article CAS PubMed Google Scholar
• Nishimura, J. et al. Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine (Baltimore) 83, 193–207 (2004).
  Article Google Scholar
• Hill, A. et al. High definition contrast-enhanced MR imaging in paroxysmal nocturnal hemoglobinuria (PNH) suggests a high frequency of subclinical thrombosis. Blood 108, 979 (2006).
  Article CAS Google Scholar
• Rother, R.P. et al. Expression of recombinant transmembrane CD59 in paroxysmal nocturnal hemoglobinuria B cells confers resistance to human complement. Blood 84, 2604–2611 (1994).
  CAS PubMed Google Scholar
• Nishimura, J. et al. Efficient retrovirus-mediated PIG-A gene transfer and stable restoration of GPI-anchored protein expression in cells with PNH phenotype. Blood 97, 3004–3010 (2001).
  Article CAS Google Scholar
• Yonemura, Y. et al. Paroxysmal nocturnal haemoglobinuria with coexisting deficiency of the ninth component of complement: lack of massive haemolytic attack. Br. J. Haematol. 74, 108–113 (1990).
  Article CAS PubMed Google Scholar
• Hillmen, P. et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 350, 552–559 (2004).
  Article CAS PubMed Google Scholar
• Hillmen, P. et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 355, 1233–1243 (2006).
  Article CAS PubMed Google Scholar
• Schrezenmeier, H. et al. Safety and efficacy of the terminal complement inhibitor eculizumab in patients with paroxysmal nocturnal hemoglobinuria: SHEPHERD phase III clinical study results. Haematologica 92, 1696 (2007).
  Google Scholar
• Muus, P. et al. The clinical benefit of eculizumab is demonstrable in all subpopulations of patients with paroxysmal nocturnal hemoglobinuria (PNH) with hemolysis. Haematologica 92, 379 (2007).
  Google Scholar
• Hillmen, P. et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood, published online 16 August 2007 (doi 10.1182/blood-2007-1106-095646).
• Wang, H. et al. Prevention of acute vascular rejection by a functionally blocking anti-C5 monoclonal antibody combined with cyclosporine. Transplantation 79, 1121–1127 (2005).
  Article CAS PubMed Google Scholar
• Biesecker, G. & Gomez, C.M. Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C6. J. Immunol. 142, 2654–2659 (1989).
  CAS PubMed Google Scholar
• Christadoss, P. C5 gene influences the development of murine myasthenia gravis. J. Immunol. 140, 2589–2592 (1988).
  CAS PubMed Google Scholar
• Morgan, B.P. et al. The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice. Clin. Exp. Immunol. 146, 294–302 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Sawant-Mane, S., Clark, M.B. & Koski, C.L. In vitro demyelination by serum antibody from patients with Guillain-Barre syndrome requires terminal complement complexes. Ann. Neurol. 29, 397–404 (1991).
  Article CAS PubMed Google Scholar
• Willison, H.J. Basic and clinical aspects of autoimmune disorders in peripheral nerves. Acta Neurol. Scand. Suppl. 183, 14–18 (2006).
  Article CAS PubMed Google Scholar
• Girardi, G. et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J. Clin. Invest. 112, 1644–1654 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Ritis, K. et al. A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J. Immunol. 177, 4794–4802 (2006).
  Article CAS PubMed Google Scholar
• Keegan, M. et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 366, 579–582 (2005).
  Article PubMed Google Scholar
• Peng, T. et al. Role of C5 in the development of airway inflammation, airway hyperresponsiveness, and ongoing airway response. J. Clin. Invest. 115, 1590–1600 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Nozaki, M. et al. Drusen complement components C3a and C5a promote choroidal neovascularization. Proc. Natl. Acad. Sci. USA 103, 2328–2333 (2006).
  Article CAS PubMed PubMed Central Google Scholar